CINECA IRIS Institutional Research Information System

FONTANINI, GABRIELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.103
EU - Europa 7.319
AS - Asia 3.726
AF - Africa 321
SA - Sud America 66
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 9
Totale 30.559
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.608
IT - Italia 2.052
CN - Cina 1.620
DE - Germania 1.306
SE - Svezia 1.198
SG - Singapore 975
BG - Bulgaria 896
GB - Regno Unito 494
CA - Canada 490
TR - Turchia 482
UA - Ucraina 439
VN - Vietnam 367
FI - Finlandia 308
CI - Costa d'Avorio 188
CH - Svizzera 132
RU - Federazione Russa 128
HK - Hong Kong 117
AT - Austria 110
FR - Francia 100
IN - India 96
SN - Senegal 76
BR - Brasile 59
BE - Belgio 54
NG - Nigeria 39
NL - Olanda 19
PL - Polonia 16
AU - Australia 14
ID - Indonesia 13
ES - Italia 11
BJ - Benin 10
JP - Giappone 10
RO - Romania 10
CZ - Repubblica Ceca 9
DK - Danimarca 9
EU - Europa 9
IL - Israele 9
KR - Corea 8
IE - Irlanda 5
HU - Ungheria 4
IR - Iran 4
TH - Thailandia 4
AL - Albania 3
LU - Lussemburgo 3
MD - Moldavia 3
MX - Messico 3
PK - Pakistan 3
TW - Taiwan 3
AR - Argentina 2
EE - Estonia 2
EG - Egitto 2
GE - Georgia 2
GR - Grecia 2
IQ - Iraq 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
MY - Malesia 2
PT - Portogallo 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AZ - Azerbaigian 1
BD - Bangladesh 1
CL - Cile 1
CO - Colombia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EC - Ecuador 1
LK - Sri Lanka 1
LY - Libia 1
MA - Marocco 1
MT - Malta 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
PY - Paraguay 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 30.559
Salva come PNG Salva come JPEG
Città #
Fairfield 2.258
Woodbridge 2.132
Chandler 1.732
Houston 1.588
Ann Arbor 1.415
Ashburn 1.134
Seattle 951
Sofia 896
Wilmington 849
Cambridge 798
Beijing 588
New York 532
Jacksonville 471
Singapore 464
Ottawa 460
Boardman 426
Milan 391
Princeton 390
Lawrence 363
Izmir 326
Medford 324
Nanjing 292
Santa Clara 285
Des Moines 258
Serra 245
Pisa 210
Abidjan 188
Florence 174
Dong Ket 163
Dearborn 155
Istanbul 140
Boulder 133
Bern 124
San Diego 114
Hong Kong 107
Vienna 107
Nanchang 98
Falls Church 89
Bremen 82
Kunming 79
Ogden 78
Frankfurt am Main 77
Dakar 76
Jüchen 70
Lancaster 67
London 63
Brussels 51
Hebei 50
Shenyang 50
Pune 47
Redwood City 47
Shanghai 40
Lagos 39
Changsha 38
Los Angeles 38
Hefei 37
Jiaxing 37
Fuzhou 35
Rome 33
Seacroft 30
Chicago 29
Düsseldorf 29
Tianjin 27
Washington 27
Norwalk 24
Nürnberg 24
Auburn Hills 22
Dallas 22
Guangzhou 22
Hangzhou 21
Quanzhou 21
Jinan 19
Orange 19
Phoenix 19
Verona 17
Kent 15
Vicopisano 15
San Francisco 14
Rho 13
Warsaw 13
Toronto 12
Bologna 11
Changchun 11
Cotonou 10
Indiana 10
Marseille 10
Lucca 9
Sezze 9
São Paulo 9
Council Bluffs 8
Edinburgh 8
Genoa 8
Lanzhou 8
Redmond 8
Turin 8
Alessandria 7
Baotou 6
Capannori 6
Lappeenranta 6
Las Vegas 6
Totale 23.116
Salva come PNG Salva come JPEG
Nome #
null 346
La densità microvascolare (DMV) come marker prognostico e predittivo nelle neoplasie maligne dell'albero bronchiale in fase avanzata. 221
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. 189
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines 180
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 167
An atypical presentation of sporadic adult-onset centronuclear myopathy 162
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 159
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. 155
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 154
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts 152
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 149
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 146
Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience 146
Reply to P.M. Foye ( Letter ) 144
Second primary lung cancer and relapse: treatment and follow-up. 143
KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 142
Evaluation of telomerase in the development and progression of colon cancer. Int J Mol Med. 2002 Nov;10(5):589-92 140
Percutaneous radiofrequency ablation (pRTA) of pulmonary tumors 140
null 138
Advanced stage thymomas and thymic carcinomas: results of multimodality treatments 137
Aberrant expression of anaplastic lymphoma kinase in lung adenocarcinoma: Analysis of circulating free tumor RNA using one-step reverse transcription-polymerase chain reaction 134
Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report 134
A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma 131
EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center 131
null 130
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 129
TERMOABLAZIONE DI NEOPLASIE POLMONARI MALIGNE: QUALI PROSPETTIVE 129
null 129
Distinct Angiogenic microRNA-mRNA Expression Profiles Among Subtypes of Lung Adenocarcinoma. 128
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas 127
Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas 127
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases 126
Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features 125
Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma 125
Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance 124
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 123
Alterations of Fas (APO-1/CD95) gene and its relationship with p53 in non small cell lung cancer 122
Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. 122
210P: Digital gene expression profiling to separate malignant pleural mesothelioma from benign reactive mesothelial hyperplasia 122
KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease 122
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 117
null 116
Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology? 116
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. 116
ANTIGENIC EXPRESSION OF M2 PYRUVATE-KINASE IN COLON RECTAL CANCER.PRELIMINARY RESULTS OF AN IMMUNOISTCHEMICAL STUDY 115
KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung 115
A high vascular count and overexpression of Vascular Endothelial Growth Factor (VEGF) are associated with unfavorable prognosis in operated Small Cell Carcinoma (SCLC) 114
Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients 114
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 114
FR-MLV INFECTION INDUCES ERYTHROLEUKEMIA INSTEAD OF LYMPHOID LEUKEMIA IN MICE GIVEN PITUITARY GRAFTS 113
Accumulation of gene protein product P53 correlates with high microvessel count in non small cell lung carcinomas 112
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A 112
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 112
null 111
Neoangiogenesis as prognostic indicator of survival in lung cancer. 111
null 111
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. 110
A gene-expression-based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations. 110
KRAS and BRAF mutational analyses in a phase II trial of first-line folfoxiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 108
Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study 108
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 108
miR-19a and miR-20a and tissue factor expression in activated human peripheral blood mononuclear cells 108
Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: A literature review 108
Nodal upstaging evaluation in NSCLC patients treated by robotic lobectomy 108
Applications of tissue microarray technology in immunohistochemistry: a study on c-kit expression in small cell lung cancer 107
CD34 microvessel density and VEGF expression in basal and squamous cell carcinoma 107
Pre-treatment EGFR-T790M subclones in lung adenocarcinoma harboring activating mutation of EGFR: a positive prognostic factor for survival? 107
Folfoxiri plus bevacizumab as first-line treatment in braf mutant metastatic colorectal cancer. 107
Screen-detected multiple primary lung cancers in the ITALUNG trial 107
2ND PRIMARY LUNG-CANCER AND RELAPSE - TREATMENT AND FOLLOW-UP 106
MicroRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers 106
Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer 105
WWOX expression in different histologic types and subtypes of non-small cell lung cancer 105
KRAS and BRAF genotyping of synchronous colorectal carcinomas. 105
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 105
Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma 104
P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC). 104
Mutations of Fas (APO-1/CD95) and p53 genes in nonmelanoma skin cancer 103
null 103
Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial 103
THE EXPRESSION OF PROLIFERATING CELL NUCLEAR ANTIGEN IN PARAFFIN SECTIONS OF PERIPHERAL, NODE-NEGATIVE NON-SMALL-CELL LUNG-CANCER 102
A preliminary study on radiofrequency thermal ablation of lung tumors 102
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts). 102
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected adenocarcinomas of the stomach and gastro-esophageal junction 102
ANGIOGENIC POTENTIAL IN-VIVO BY KAPOSIS-SARCOMA CELL-FREE SUPERNATANTS AND HIV-1 TAT PRODUCT - INHIBITION OF KS-LIKE LESIONS BY TISSUE INHIBITOR OF METALLOPROTEINASE-2 101
Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice 101
Potentiation of the malignant phenotype of the undifferentiated aro thyroid cell line by insertion of the bcl-2 gene 101
Novel MTCYB mutation in a young patient with recurrent stroke-like episodes and status epilepticus 101
Neoangiogenesis: A putative marker of malignancy in non-small-cell lung cancer (NSCLC) development 100
Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. 100
Markers of cell proliferation as prognostic factors in differentiated thyroid cancer. 99
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma 99
Overexpression of the cohesin-core subunit SMC1A contributes to colorectal cancer development. 99
VALUTAZIONE DELL'ATTIVITA' TELOMERASICA E DELL'ESPRESSIONE DI hTERT mRNA IN ADENOCARCINOMA DEL COLON 98
Evaluation of telomerase in non-melanoma skin cancer 98
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest 98
Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. 98
null 98
BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features. 97
Distal embolization during primary angioplasty: histopathologic features and predictability 97
Totale 12.214
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.703
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.703
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.150 0 0 0 0 662 652 723 484 593 451 478 107
2020/20212.840 271 158 217 112 372 146 176 271 271 215 164 467
2021/20224.001 48 289 112 219 757 636 105 193 200 168 155 1.119
2022/20234.685 551 537 294 478 558 653 25 376 840 19 324 30
2023/20242.972 315 316 392 140 432 585 84 84 80 45 150 349
2024/20251.706 82 447 86 647 444 0 0 0 0 0 0 0
Totale 31.140